Disease/Infection News

RSS

First demonstration of COVID-19-like response by an essential virus encoded protein by SARS-CoV-2 in vivo

Researchers from collaborating universities in Virginia have recently utilized transgenic mice to explore the effects of SARS-CoV-2 on associated lung injury.

30 Jun 2021

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

The study, published in the journal Cell Reports, showed that the mutations in the virus, particularly the deletion of two amino acids H69/V70 seen in the Alpha variant (B.1.1.7), enables the virus to overcome weaknesses as it evolves.

30 Jun 2021

Behavior modification key to prevent COVID-19, study shows

One of the longest-running studies examining COVID-prevention behaviors shows hygiene changes have been sustained but not complex changes, like social distancing, with important policy implications.

30 Jun 2021

Novel candidate malaria vaccine confers high levels of durable protection

Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites.

30 Jun 2021

Frequent testing increases chance of detecting COVID-19 infections

The chance of detecting the virus that causes COVID-19 increases with more frequent testing, no matter the type of test, a new study found. Both polymerase chain reaction and antigen tests, paired with rapid results reporting, can achieve 98% sensitivity if deployed at least every three days.

30 Jun 2021

Antibody development against SARS-CoV-2 following Moderna vaccine

In a paper recently uploaded to the preprint server medRxiv* by Belda et al. (June 27th, 2021) two seroconversion panels containing the sera of individuals that received the Moderna (mRNA-1273) vaccine are compared, and the impact on neutralizing IgG antibody titers in these individuals is analyzed.

30 Jun 2021

Moderna's COVID vaccine effective against emerging variants including Delta

Researchers in the United States have analyzed the neutralizing activity of Moderna’s mRNA-1273 vaccine against several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

Study provides important insights into early stages of SARS-CoV-2 infection

Researchers in the UK have provided important new insights into the early stages of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

Sanaria researchers make progress in the development of highly protective malaria vaccine

Researchers from Sanaria Inc. and the National Institutes of Health are making progress in the development of highly protective malaria vaccines.

30 Jun 2021

UC screening program helps detect HIV outbreaks among persons who inject drugs

Newly published research shows that a screening program in the University of Cincinnati Medical Center Emergency Department helped detect an outbreak of HIV among persons who inject drugs in Hamilton County, Ohio, from 2014-18.

30 Jun 2021

Solar irradiation inactivates SARS-CoV-2 and other human coronaviruses, finds study

Coronaviruses irradiated with simulated sunlight used to infect cells showed reduced infectivity and reduced viral replication compared to viruses that were not irradiated.

30 Jun 2021

Employed individuals more likely to be infected with the flu virus

A University of Arkansas researcher and international colleagues found that employed individuals, on average, are 35.3% more likely to be infected with the flu virus.

30 Jun 2021

New research receives $2 million grant to determine if meningitis, sepsis increase Alzheimer's risk

The role of peripheral and brain infections in the development of Alzheimer's disease is the focus of new research at The University of Texas Health Science Center at Houston, funded with a $2 million grant from the National Institutes of Health.

30 Jun 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.

30 Jun 2021

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

A new study in the UK, by researchers at Imperial College London, The Francis Crick Institute and the University of Glasgow, explores the loss of coronavirus disease 2019 (COVID-19) vaccine efficacy against the virus behind the current pandemic caused by the emergence of newer variants that have undergone mutational escape.

30 Jun 2021

Effectively monitoring COVID-19 in reopened educational institutions: the San Diego model

An interesting new study from the University of California San Diego (UCSD) shows that using preventive measures to block viral transmission, coupled with repeated testing and rapid turnaround times for the results, can successfully prevent outbreaks associated with the reopening of educational institutions.

30 Jun 2021

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

A new preprint on the medRxiv* server adds fuel to this train of thought, showing that the required cell program is already active in children – namely, a higher expression of specific pattern recognition receptors (PRRs), which mediate an interferon (IFN) response.

30 Jun 2021

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

New clinical trial data, recently published in The Lancet’s Infectious Diseases, presents an initial report on the effect of an inactivated SARS-CoV-2 vaccine, CoronaVac, on children and adolescents from ages 3-17 in a double-blind, randomized setting.

30 Jun 2021

Researchers launch a new smell training device for rehabilitation after Covid-19

Smell training used to be mainly a thing for wine enthusiasts, gourmets, and perfumers. But Covid-19 changed all that, and now Malmö University researchers have launched a new smell training device.

30 Jun 2021

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.

30 Jun 2021

Disease/Infection News

First demonstration of COVID-19-like response by an essential virus encoded protein by SARS-CoV-2 in vivo

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

Behavior modification key to prevent COVID-19, study shows

Novel candidate malaria vaccine confers high levels of durable protection

Frequent testing increases chance of detecting COVID-19 infections

Antibody development against SARS-CoV-2 following Moderna vaccine

Moderna's COVID vaccine effective against emerging variants including Delta

Study provides important insights into early stages of SARS-CoV-2 infection

Sanaria researchers make progress in the development of highly protective malaria vaccine

UC screening program helps detect HIV outbreaks among persons who inject drugs

Solar irradiation inactivates SARS-CoV-2 and other human coronaviruses, finds study

Employed individuals more likely to be infected with the flu virus

New research receives $2 million grant to determine if meningitis, sepsis increase Alzheimer's risk

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

Effectively monitoring COVID-19 in reopened educational institutions: the San Diego model

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

Researchers launch a new smell training device for rehabilitation after Covid-19

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News